首页> 外文期刊>Archives of medical research >Model of the TBP-TFIIB complex from Plasmodium falciparum: interface analysis and perspectives as a new target for antimalarial design.
【24h】

Model of the TBP-TFIIB complex from Plasmodium falciparum: interface analysis and perspectives as a new target for antimalarial design.

机译:恶性疟原虫TBP-TFIIB复合物的模型:界面分析和观点作为抗疟疾设计的新目标。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Malaria affects 200-300 million individuals per year worldwide. Plasmodium falciparum is the causative agent of the most severe and mortal type of malaria. The need for new antimalarials comes from the widespread resistance to those in current use. New antimalarial targets are required to increase chemical diversity and effectiveness of the drugs. The research for such new targets and drug chemotypes is aided by structure-based drug design. We present a model of the TBP-TFIIB complex from P. falciparum (pfTBP-pfTFIIB) and a detailed study of the interactions at the TBP-TFIIB interface. METHODS: The model was built using standard methodology, optimized energetically and evaluated structurally. We carried out an analysis of the interface considering its evolution, available experimental data on TBP and TFIIB mutants, and the main conserved and non-conserved interactions. To support the perspective of using this complex as a new target for rational antimalarial design, we present the comparison of the pfTBP-pfTFIIB interface with its human homolog. RESULTS: Despite the high residue conservation at the interface, we identified a potential region, composed of species-specific residues that can be used for rational antimalarial design. CONCLUSIONS: Currently there are no antimalarial drugs targeted to stop the nuclear transcription process, a vital event for all replication stages of P. falciparum. Due to its absolute requirement in transcription initiation, we consider the pfTBP-pfTFIIB interface as a new potential target for novel antimalarial chemotypes.
机译:背景:疟疾每年影响全世界200-300百万人。恶性疟原虫是最严重和致命的疟疾类型的病原体。对新抗疟药的需求来自对当前使用抗疟药的广泛抵抗。需要新的抗疟目标以增加药物的化学多样性和有效性。基于结构的药物设计有助于对这类新靶标和药物化学型的研究。我们提出了恶性疟原虫TBP-TFIIB复合体的模型(pfTBP-pfTFIIB),以及在TBP-TFIIB界面相互作用的详细研究。方法:采用标准方法建立模型,进行能量优化和结构评估。我们对界面进行了分析,考虑了界面的演变,TBP和TFIIB突变体的可用实验数据以及主要的保守和非保守相互作用。为了支持将这种复合物用作合理的抗疟疾设计新目标的观点,我们提出了pfTBP-pfTFIIB接口与其人类同源物的比较。结果:尽管在界面处有很高的残基保守性,我们仍确定了一个潜在的区域,该区域由可用于合理抗疟设计的物种特异性残基组成。结论:目前尚无抗疟药物靶向核转录过程,这是恶性疟原虫所有复制阶段的重要事件。由于其对转录起始的绝对要求,我们认为pfTBP-pfTFIIB接口是新型抗疟药化学型的新潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号